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Background: According to the Spanish Society of Cardiology, 700,000 patients receive oral anticoagulants, and in 
these cases bleeding on probing (BOP) could be altered. However, no studies have analyzed the periodontal status 
of these patients and the effects anticoagulants may have upon BOP. 
A study was made of the possible relationship between plaque index, probing depth, INR (International Normalized 
Ratio) and acenocoumarol dose versus the clinical signs of BOP in a sample of anticoagulated patients. Likewise, 
an analysis was made of oral hygiene habits and attitude towards bleeding in these patients.
Material and Methods: A controlled observational clinical study was made in La Ribera Hospital (Valencia, Spain) 
involving 44 anticoagulated patients treated with Sintrom® (acenocoumarol) and a homogeneous control group of 
44 non-anticoagulated patients. A survey on oral hygiene habits and attitude towards bleeding was carried out, and 
the main periodontal parameters were recorded. 
Results: Probing depth was the parameter with the strongest correlation to BOP (p<0.001), followed by the plaque 
index (p<0.002). In contrast, no relationship was observed between acenocoumarol dose or INR and BOP. Mean 
BOP was greater in the control group than in the anticoagulated group (p<0.001). Oral hygiene habits and attitude 
towards bleeding differed significantly between groups.
Conclusions: We have found no explanation why BOP was greater in the control group. What seems clear is that 
in the presence of the same plaque index and probing depth, anticoagulated patients did not bleed more than non-
anticoagulated patients. A lack of knowledge of health and oral hygiene habits was observed in these subjects.
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Introduction
According to the Spanish Society of Cardiology, 700,000 
patients receive oral anticoagulation therapy (OAT). The 
aim of such treatment is to prevent thromboembolic di-
sease, one of the leading causes of disability and death 
beyond the fifth decade of life (1). The drugs used in 
OAT are coumarin derivatives known as vitamin K anta-
gonists, since they are structural analogs of this vitamin. 
The most representative drugs in this category are war-
farin (Aldocumar®) and acenocoumarol (Sintrom®). 
Both of them are derived from 4-hydroxycoumarin, and 
the differences between the two molecules are basically 
of a pharmacokinetic and pharmacodynamic nature (2).
From the pharmacodynamic perspective, both warfarin 
and acenocoumarol interfere with vitamin K metabo-
lism, lowering the plasma levels of the vitamin K-de-
pendent coagulation factors (Factors II, VII, IX and X) 
and of two natural coagulation inhibitors: proteins S and 
C. These drugs exert their effect within the liver cell mi-
crosomes, inhibiting the reductase required for transfor-
ming inactive vitamin K into active vitamin K (2).
The International Normalized Ratio (INR) is used to 
monitor anticoagulant activity. It expresses the ratio bet-
ween prothrombin time (PT) and PT raised to the power 
of the International Sensitivity Index (ISI). In the case of 
a healthy individual not receiving OAT, the normal INR 
is between 0.9-1.1, while two therapeutic ranges are 
used in the case of patients subjected to OAT: the first 
INR range (2.5-3.5) applies to patients with mechanical 
valve prostheses, while the second range (2,3) applies to 
the rest of cardiac disorders (2).
The mean acenocoumarol dose is between 2-4 mg/day. 
With advancing age, dose reductions prove necessary. 
In addition to old age and polymedication, many other 
circumstances can account for the great variability in 
individual response to OAT, including genetic factors 
related to isoenzyme CYP2C9 (which mediates meta-
bolization of the drug) and non-genetic factors such as a 
lack of adherence to therapy or dosing error; modifica-
tions induced by other concomitant drug treatments, her-
bal remedies or homeopathic products; changes in diet; 
or intercurrent medical diseases or other comorbidities 
such as diarrhea, among other alterations (2). Due to the 
great variability in treatment response, anticoagulated 
patients are subjected to periodic controls to determine 
the INR value and adjust the drug dose according to this 
parameter and other blood markers. In dental practice, 
many procedures can result in bleeding, including par-
ticularly tooth extraction and surgery. In such situations 
the bleeding risk would be increased in patients receiving 
OAT. The current recommendations are to not suspend 
anticoagulation in simple extractions and oral surgeries 
involving a low bleeding risk, provided the patient INR 
values are within the therapeutic range. In the case of 
more complicated surgery or in the presence of an in-
creased bleeding risk, joint assessment of the case with 
the hematologist is required, and the suspension of OAT 
with the administration of low molecular weight heparin 
(LMWH) may prove necessary in some cases (3-6).
Importance of bleeding on probing (BOP)
Bleeding on probing (BOP) is a basic clinical exploratory 
sign used to evaluate gingival inflammation (7). Diffe-
rent indices are used for this purpose, though regardless 
of which of them is used, positive bleeding on probing 
is indicative of gingival inflammation. The diagnostic 
usefulness of BOP is undeniable, though its prognostic 
value is less clear. Many authors have concluded that the 
presence of BOP does not indicate an increased risk of 
destruction of tissue and supporting bone, i.e., this clini-
cal sign has a low positive predictive value (8-10). From 
the perspective of periodontal treatment, however, it is 
essential to ensure healthy gums, without inflammation 
and therefore without BOP.
In 1991, Lang et al. (9) studied a group of 41 patients 
subjected to maintenance periodontal treatment, and 
found that in those zones where BOP proved positive, 
subsequent progression towards clinical attachment loss 
was seen in only 6% of the cases. In turn, in those zones 
where BOP proved negative, 98% of the cases remained 
stable. This study therefore underscored the high negati-
ve predictive value of BOP.
As has been mentioned, gingival inflammation is related 
to BOP. When a periodontal probe is inserted between 
the gums and the tooth (subgingival zone), the blunt tip 
of the probe comes into contact with the inflamed, thin-
ned or ulcerated gingival epithelium, causing the rupture 
of small capillaries dilated as a result of the connective 
tissue inflammation (10). In view of the clinical impor-
tance of BOP, different factors that may influence this 
parameter have been analyzed with the purpose of stan-
dardizing this type of periodontal exploration. Factors 
inherent to the periodontal probe have been considered, 
such as the diameter of the tip of the instrument, its an-
gulation (10,11) and the pressure applied on probing 
(12). 
Smoking is another factor that can alter BOP, resulting in 
a decrease in the incidence of bleeding (13,14). In 2003, 
Nair et al. showed that smoking can induce false-nega-
tive results with the BOP test. In a group of 27 smokers 
these authors found the BOP rate to have doubled four 
weeks after smoking cessation (from 16% to 32%) (15).
Some investigators have described the effect of antipla-
telet drugs upon BOP. In 2002, Schrodi et al. assessed 
the effect of acetylsalicylic acid (Aspirin®) in patients 
without periodontal disease, and found a dose of 325 
mg/day during one week to cause an increase in percen-
tage BOP – particularly in individuals who previously 
presented BOP at 30% or more of the explored sites 
(16). Likewise, in 2004, Royzman et al., in a sample of 
patients with gingivitis, found the administration of 81 
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to 325 mg/day of Aspirin® during one week to produ-
ce a significant increase in percentage BOP(14). It the-
refore can be concluded that antiplatelet medication is 
an aspect to be taken into account in the context of the 
patient anamnesis in order to correctly assess the true 
significance of BOP at periodontal exploration, since 
such medication may lead to error as a result of the as-
sociated increase in BOP. It may be inferred that anti-
coagulants, in the same way as antiplatelet drugs, act as 
BOP-modifying factors, though the pharmacodynamic 
characteristics of the two classes of drugs differ. Howe-
ver, despite the possible implication of anticoagulants 
as BOP-modifying factors, no data are available in the 
literature on the relationship between BOP and anticoa-
gulant use. Likewise, no publications have been found 
on the oral health of patients subjected to OAT or their 
oral hygiene habits – these being very important factors 
particularly in patients of this kind, where prevention is 
a need rather than a preference, since the ultimate aim is 
to avoid more invasive procedures that might result in 
bleeding complications.
Oral anticoagulation therapy is the management of choi-
ce in certain cardiac disorders typically seen in the se-
cond half of life, and it is precisely in this age period 
when periodontal disease becomes more prevalent (18) 
and the conditions inherent to aging – such as diminis-
hed salivary flow and lowered host defenses – can lead 
to different kinds of oral diseases. All this and the lack 
of education in oral health among the more elderly po-
pulation, as well as concerns about bleeding in these an-
ticoagulated individuals, may contribute to worsen oral 
hygiene, as pointed out by Padrón et al. in 2003 (19). As 
a result, tooth extractions in patients subjected to OAT 
are quite frequent with the consequent healthcare costs 
and impact upon patient oral health. Furthermore, these 
subjects are at risk of suffering bleeding complications 
during or after the operation.
The aim of this study was to analyze the periodontal 
health, oral hygiene habits and attitude towards blee-
ding of a sample of anticoagulated patients, and to exa-
mine factors such as plaque index, probing depth, ace-
nocoumarol dose and INR value, in order to determine 
whether OAT is implicated in BOP.
Material and Methods
A controlled observational clinical study was carried 
out in a population sample of 44 individuals subjected 
to OAT with acenocoumarol (Sintrom®) and a homo-
geneous control group of 44 subjects without anticoa-
gulation.
Patient screening. The study was carried out in the De-
partment of Hematology of La Ribera University Hos-
pital (Alzira, Spain). The patients were included on a 
consecutive basis in the order in which they were seen 
in the Department. The study was approved by the local 
Clinical Research Ethics Committee, and written infor-
med consent was obtained from all the patients.
Inclusion and exclusion criteria. The study was limited 
to patients receiving acenocoumarol (Sintrom®), i.e., 
other forms of anticoagulation such as subcutaneous low 
molecular weight heparin (LMWH) were excluded. Pa-
tients outside the 40-80 years age range were excluded, 
as were smokers or subjects who had stopped smoking 
less than a year ago, patients wearing removable dentu-
res with fewer than 18 teeth in the mouth, individuals 
with more than two dental implants, and patients who 
had received periodontal treatment, systemic or local 
antimicrobials or any type of antiinflammatory medica-
tion in the three months before the exploration. Lastly, 
we also excluded patients receiving antiplatelet drugs or 
immunosuppressors, and pregnant or nursing women. 
These same exclusion criteria were applied to the con-
trol group, with the sole difference that these individuals 
were not receiving anticoagulants.
Study procedure and clinical recordings. The entire pro-
cedure and the recordings were carried out by the same 
individual blinded to the type of exploration. In a first 
phase we administered a questionnaire comprising basic 
questions on oral hygiene – some of a dichotomic (yes/
no) nature and others involving short answers.
The daily dose of acenocoumarol (Sintrom®) adminis-
tered to each patient was recorded, along with the INR 
value at the time of the survey. Following this first phase 
of the study, those patients that met all the inclusion cri-
teria entered the second or periodontal evaluation phase. 
The plaque index was measured using a dental plaque 
revealer (Plac-Control®; floxin B 1.4%). We recorded 
the plaque scores for each tooth using the Quigley-Hein 
plaque index (1962) posteriorly modified by Turesky-
Gilmore-Glickman (20), centering plaque measurement 
on the gingival third at three points of the buccal dental 
surface. After recording the plaque values in the perio-
dontogram, all teeth present in the mouth were subjected 
to periodontal probing on the three buccal surfaces (me-
siobuccal, medial and distobuccal).
The following parameters were recorded in the perio-
dontogram: probing depth, plaque index and the presen-
ce of BOP (Fig. 1). Bleeding on probing was considered 
positive when bleeding was observed 20 seconds after 
probing (21,22).
The same exploration was carried out in both the anti-
coagulated patients and the control group.
Statistical analysis
Descriptive, bivariate and multivariate analyses were 
performed in order to define a mathematical expression 
allowing us to account for BOP according to the rest of 
the periodontal parameters and the use or not of oral anti-
coagulant drugs. A multiple linear regression model was 
generated, with inclusion of all the factors in order to 
assess possible confounding effects and develop a fully 
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Fig. 1: Bleeding on probing.
adjusted final model. The usual applicability hypothe-
ses were validated for the optimized model: normality 
of residuals, homoscedasticity, autocorrelation (Durbin-
Watson) and non-colinearity. The accepted statistical 




N 88 44 44
Mean 62,58 60,73 64,43
Standad Deviation 9,69 9,56 9,56
Minimum 40 43 40
Maximum 80 78 80
Median 64 62 66,50
PLAQUE INDEX
N 88 44 44
Mean 2,31 2,18 2,44
Standard Deviation 1,14 0,88 1.34
Minimum 0,4 0,8 0,4
Maximum 5 4,3 5
Median 2,02 2,02 2,10
DEPTH ON PROBE
N 88 44 44
Mean 2,81 2,49  * 3,13  *
Standard Deviation 0,88 0,61 0,99
Minimum 1,7 1,7 1,8
Maximum 5,8 4,5 5,8
Median 2,63 2,37 2,88
BLEED ON PROBE
N 88 44 44
Mean 25,49 36,05  * 14,92  *
Standard Deviation 23,50 26,87 12,93
Minimum 0 0 1,2
Maximum 100 100 61,1
Median 18,51 34,48 12,05
Results
The final study sample consisted of 88 individuals divi-
ded into two groups: 44 anticoagulated patients and 44 
controls. The mean age was 62.6 ± 9.7 years (range 40-
80). The two groups were homogeneous in terms of age 
and plaque index (Table 1).
The mean probing depth differed significantly between 
the two groups, being greater among the anticoagulated 
patients than in the controls (p<0,001) (Table 1).
-Bleeding on probing
The mean incidence of BOP was significantly greater 
in the control group than in the anticoagulated patients 
(36.05% versus 14.92%, respectively; p<0.001) (Fig. 2). 
Bleeding on probing was found to be significantly corre-
lated (p<0.001) to both plaque index and probing depth. 
The multivariate linear regression model in turn showed 
probing depth to be the parameter with the greatest ca-
pacity to account for BOP (p<0.001). For each millime-
ter increase in probing depth, BOP was seen to increase 
23.7%. This observation proved valid for individuals of 
the same group, plaque index, age and attitude towards 
Table 1: Homogeneity of control and test groups for age, plaque index, depth on probe and bleed on probe.
• Statistically significant differences between two groups (p<0,05).
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Fig. 2: Box-plot showing BOP percentage in both groups.
bleeding. However, the level of significance between pa-
tient group and probing depth suggests that the relation-
ship between BOP and probing depth differs according 
to whether anticoagulation is administered or not. The 
impact upon BOP was seen to increase with increasing 
probing depth in the control group. With regard to the 
plaque index, the findings were similar (p<0.002), and 
we moreover observed a strong group interaction ten-
dency. For each additional point increment in the plaque 
index score, BOP was found to increase 9.9% on avera-
ge. In effect, for a similar plaque index, the controls are 
expected to present a much higher BOP rate. All these 
conclusions related to bacterial plaque were also adjus-
ted for the rest of the factors in the model, i.e., age and 
attitude towards bleeding. 
-Questionnaire
As reflected by the results of the questionnaire, the oral 
hygiene conditions and attitude towards bleeding were 
seen to differ significantly between the two groups.
Interdental brushing was more frequent in the control 
group (27.3% versus 11.4% in the OAT group). Regar-
ding the attitude towards bleeding, the anticoagulated 
patients were seen to be more concerned about bleeding: 
65.9% claimed to fear bleeding in general (i.e., affec-
ting any body location), versus only 9.1% of the con-
trols. Furthermore, 29.5% of the anticoagulated patients 
claimed to be afraid of bleeding of the gums, versus 
only 13.6% of the controls. However, when asked about 
bleeding on brushing their teeth, 88.6% of the controls 
claimed to notice bleeding, versus 65.9% of the anticoa-
gulated patients. On the other hand, in relation to fear of 
bleeding, 41% of the anticoagulated patients claimed to 
stop brushing when bleeding occurred, versus only 7% 
of the controls.
Another conclusion drawn from the questionnaire was 
that a larger percentage of controls were aware of the 
existence of periodontal disease and its treatment (18.4% 
versus only 5.4% of the anticoagulated patients). 
Regarding the perceived cause of gingival bleeding, 
most of the anticoagulated patients either considered 
bleeding to be due to Sintrom® (34%) or were unable to 
specify the reason for bleeding (38.6%). In the control 
group, vigorous brushing (27.3%) and gingival inflam-
mation (38.6%) were the main reasons given for gingi-
val bleeding. 
The results obtained are shown in Table 2.
Discussion
A curious finding of our study was that under homoge-
neous plaque index, probing depth and age conditions, 
the anticoagulated patients were seen to present less 
BOP than the controls. The explanation for this may 
reside in the possible effects of the anticoagulant me-
dication upon local inflammatory reaction; the possible 
concomitant diseases of the patients; interactions with 
other drug substances; or simply other factors not consi-
dered in our study. 
In relation to the descriptive analysis of the results obtai-
ned in the OAT group, we attempted to correlate the Sin-
trom® dose and INR value to BOP. In the case of INR, no 
statistically significant association was found (p=0.809). 
Therefore, a greater or lesser INR value does not appear 
to be able to predict greater or lesser BOP during the 
clinical exploration of anticoagulated patients. On con-
sidering the drug dose, we found that for each additio-
nal milligram of acenocoumarol, percentage bleeding 
decreased 3.62%, i.e., the administered dose appears to 
be useful for predicting BOP (p=0.032). It cannot be ac-
cepted that an increase in acenocoumarol dose results in 
less BOP, due to the many factors that influence the dose 
administered to each patient and which have not been 
considered in our study, as well as to uncertainty regar-
ding patient adherence to therapy. In this respect, a given 
patient may have a larger prescribed dose but fail to take 
the medication as indicated. In this case the dose may 
be further increased in an attempt to reach the optimum 
INR value, though BOP would remain clinically without 
change because of treatment non-compliance.
An association was found between the drug dose and 
INR value – the subjects with the highest INR also being 
the individuals with the highest Sintrom® dose, though 
statistical significance was not reached (p=0.57). It can 
be concluded that those patients with greater difficulty in 
achieving an optimum INR normally present higher and 
more irregular doses between successive controls. 
We infer that bleeding would not be caused by aceno-
coumarol but by gingival inflammation. In pharmacody-
namic terms, it could be postulated that BOP in principle 
should not be increased in anticoagulated patients, pro-
vided they are healthy from the periodontal perspective. 
The present study involving patients and controls mat-
ched for age, characteristics and dental plaque index was 
carried out to confirm this idea.
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N % N % N % 
Use of brush 
Total 88 100 44 100 44 100 
Yes 85 96.6 44 100 41 93.2 
No 3 3.4 0 0 3 6.8 
Frequency of brushing 
0 3 3.4 0 0 3 6.8 
1 32 36.4 14 31.8 18 40.9 
2 30 34.1 16 36.4 14 31.8 
3 23 26.1 14 31.8 9 20.5 
Interdental brush 
Total 88 100 44 100 44 100 
Yes 17 19.3 12 27.3 5 11.4 
No 71 80.7 32 72.7 39 88.6 
Fear of bleeding  
Total 88 100 44 100 44 100 
Yes 33 37.5 4 9.1 29 65.9 
No 55 62.5 40 90.9 15 34.1 
Fear of gum bleeding 
Total 88 100 44 100 44 100 
Yes 19 21.6 6 13.6 13 29.5 
No 69 78.4 38 86.4 31 70.5 
Spontaneous bleeding 
Total 88 100 44 100 44 100 
Yes 23 26.1 13 29.5 10 22.7 
No 65 73.9 31 70.5 34 77.3 
Bleeding when brushing 
Total 85 100 44 100 41 100 
Yes 66 77.6 39 88.6 27 65.9 
No 19 22.4 5 11.4 14 34.1 
Stop brushing 
Total 66 100 39 100 29 100 
Yes 15 22.1 3 7.7 12 41.4 
No 53 77.9 36 92.3 17 58.6 
Cause of bleeding 
Total 88 100 44 100 44 100 
Sintrom® 15 17 0 0 15 34.1 
Strong brush 18 20.5 12 27.3 6 13.6 
Inflammation 22 25 17 38.6 5 11.4 
Does not know 26 29.5 9 20.5 17 38.6 
Other causes 7 8 6 13.6 1 2.3 
Intense bleeding 
Total 88 100 44 100 44 100 
Yes 25 28.4 10 22.7 15 34.1 
No 63 71.6 34 77.3 29 65.9 
Periodontitis Knowledge 
Total 88 100 44 100 44 100 
Yes 10 11.4 8 18.2 2 4.5 
No 78 88.6 36 81.8 42 95.5 
Dentist teaches brushing 
Total 88 100 44 100 44 100 
Yes 12 13.6 6 13.6 6 13.6 
No 76 86.4 38 86.4 38 86.4 
Where to buy brush 
Total 88 100 44 100 38 100 
Pharmacy 34 41.5 16 36.4 18 47.4 
Supermarket 48 58.5 28 63.6 20 52.6 
Schrodi et al. found that patients without periodontal di-
sease administered 325 mg/day of Aspirin® during one 
week showed an increase in BOP, particularly among 
those individuals that already presented BOP of ≥ 30% 
of the surfaces (16). In turn, Royzman et al., in patients 
with gingivitis, found that the administration of 81 to 
325 mg of Aspirin® likewise produced an increase in 
BOP (14). Two key aspects should be considered on 
analyzing these two studies and comparing them with 
our own findings in anticoagulated patients. Firstly, the 
pharmacodynamic characteristics of acetylsalicylic acid 
(Aspirin®) are completely different from those of ace-
nocoumarol (Sintrom®). Furthermore, as indicated by 
Schrodi et al. and Royzman et al., BOP increases espe-
cially in those individuals that already present gingival 
inflammation (16,17). Adding the action of Aspirin®, 
which interferes with platelet plug formation, to this sce-
nario would result in greater BOP. Probing depth is ty-
pically related to an increased plaque index, and both of 
these parameters are thus logically associated to increa-
sed BOP. In some cases, however, inactive periodontal 
pockets without BOP can be observed.
J Clin Exp Dent. 2017;9(12):e1431-8.                                                                                                                                                           Periodontal health in anticoagulated patients
e1437
On comparing the anticoagulated patients versus the 
age- and plaque index-matched controls without anti-
coagulation, we found that although the former presen-
ted a greater mean probing depth and could thus be ex-
pected to present more gingival inflammation and hence 
greater BOP, these patients paradoxically exhibited less 
BOP than the controls. The descriptive analysis of the 
anticoagulated patients showed the Sintrom® dose to 
be negatively correlated to BOP. This result therefore 
may have been underestimated and wrongly attributed 
to chance. In any case, we have no plausible explana-
tion for the abovementioned finding, though it may have 
been related to a decrease in local inflammation as a re-
sult of the action of the drug. A review of the literature 
has yielded no evidence supporting this idea, however. 
More objective data are therefore needed to clarify this 
association and discard a possible causal relationship de-
pendent upon individual variability in response to OAT.
The main limitation of our study is the limited sample 
size. Another limitation refers to the fact that we did not 
measure the characteristics of BOP, i.e., we did not eva-
luate whether OAT was associated to more profuse or 
lasting bleeding as a consequence of interference with 
the coagulation process. Lastly, we did not use a perio-
dontal probe of controlled pressure but only one experi-
mented periodoncist explored all the patients. 
With regard to the questionnaire (Table 2), the anticoa-
gulated patients expressed more fear of bleeding in ge-
neral and of gingival bleeding. However, on comparing 
the data with those of the control group, we again made 
the surprising observation that 88.6% of the controls 
claimed to experience bleeding on brushing versus only 
58% of the anticoagulated patients. It thus seems reaso-
nable to postulate improved oral hygiene in the controls, 
despite their observed greater incidence of bleeding on 
brushing. Sixty-five percent of the anticoagulated pa-
tients did not consider the situation to be anomalous but 
rather a normal condition inherent to the oral cavity. The-
se results suggest that the anticoagulated patients were 
less knowledgeable about the significance and relevance 
of gingival bleeding. The anticoagulated patients were 
seen to be unaware of the relationship between gingival 
inflammation and bleeding of the gums, and moreover 
did not know the cause of bleeding or attributed it to the 
use of Sintrom®. In contrast, the controls appeared to 
have greater awareness of the cause of bleeding.
The questionnaire was also used to investigate whether 
the anticoagulated patients were knowledgeable about 
periodontal disease and treatment. A surprising finding 
was the fact that 42 of the 44 subjects (95.4%) had never 
received periodontal treatment and were not familiari-
zed with periodontal disease. On the other hand, only 6 
of these patients (14%) had received instructions on oral 
hygiene from a dental professional.
The above observations point to the need for oral health 
education among anticoagulated patients. Oral health is 
to be promoted in patients subjected to OAT, since fa-
ilure to do so may result in an increased number of too-
th extractions and surgical procedures which logically 
imply bleeding risk and possible important alterations 
in INR secondary to either changes in anticoagulation 
allowing surgery (e.g., the administration of LMWH) or 
the postoperative high-dose analgesics and antiinflam-
matory drugs prescribed. Furthermore, surgery produces 
important patient stress, with changes in daily living 
habits after the operation. Strategies focused on tooth 
extraction should be avoided, placing emphasis on pre-
ventive measures and oral health promotion and educa-
tion to prevent bleeding among anticoagulated patients 
undergoing surgery. Such measures not only lower the 
incidence of complications but also reduce the health-
care costs.
Conclusions 
1. The patients subjected to OAT with acenocoumarol 
(Sintrom®) had little knowledge about oral health, and 
this resulted in deficient periodontal conditions. The 
questionnaire revealed a lack of awareness of periodontal 
disease and treatment. Improvements are needed in this 
regard in order to prevent aggressive surgery and teeth 
extractions from becoming the management option of 
choice, since such treatments in patients receiving OAT 
result in important surgical stress and bleeding risk.
2. We have not found an explanation why BOP was hig-
her in the control group. What seems clear is that with 
the same plaque index and probing depth, anticoagula-
ted patients did not bleed more than non-anticoagulated 
patients. 
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